Patients with lower extremity peripheral artery disease (PAD) are at increased risk of major
adverse limb events (MALE). The efficacy and safety of direct oral anticoagulants (DOACs) …

Importance Patients with symptomatic lower extremity peripheral artery disease (LE-PAD)
experience an increased risk of major vascular events. There is limited information on what …

The best method of anticoagulation for patients with peripheral artery disease (PAD) is still a
topic of interest for physicians. We conducted a meta-analysis to compare the effects of …

Lower extremity arteries might be affected by atherosclerotic peripheral arterial disease
(PAD), or by embolization causing ischaemic symptoms. Patients with PAD often have more …

Background PAD is a significant cause of morbidity and mortality affecting over 200 million
people worldwide. Current guidelines recommend at least a single antiplatelet or …

Aims Peripheral artery disease (PAD) patients suffer a high risk of major cardiovascular (CV)
events, with athero-thrombo-embolism as the underlying pathophysiologic mechanism …

Purpose To identify randomized controlled trials that compared antiplatelet monotherapy to
combination antiplatelet plus anticoagulant therapy and evaluated major adverse …

Background The efficacy and safety of non-vitamin K antagonist oral anticoagulants
(NOACs) combined with antiplatelet drugs in patients with peripheral artery disease remain …

Peripheral artery disease (PAD) is a major cause of morbidity and mortality but it is usually
underdiagnosed and undertreated. Patients with PAD present dysregulated procoagulant …

Background Patients with peripheral arterial disease (PAD) are at increased risk for major
adverse cardiovascular events (MACE) such as cardiovascular death, myocardial infarction …